This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro and Sabrina Tavernise. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at ...
…
continue reading
Inhoud geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !
Ga offline met de app Player FM !
S6 Ep29: Biosimilars Policy Roundup for April 2024—Podcast Edition
MP3•Thuis aflevering
Manage episode 416565834 series 2161808
Inhoud geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Show notes
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
150 afleveringen
MP3•Thuis aflevering
Manage episode 416565834 series 2161808
Inhoud geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Show notes
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
150 afleveringen
همه قسمت ها
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.